Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

Paclitaxel is under clinical development by DAE HWA Pharmaceutical and currently in Phase I for Kaposi Sarcoma.

Q-901 is under clinical development by Qurient and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase ...

Avelumab is under clinical development by Merck and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

TILT-123 is under clinical development by TILT Biotherapeutics and currently in Phase I for Rectal Cancer. According to GlobalData, Phase I drugs for Rectal Cancer does not have sufficient historical ...

Vilastobart is under clinical development by Xilio Therapeutics and currently in Phase II for Small-Cell Lung Cancer.

Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 30% phase transition success rate (PTSR) ...